Embody vs BreezeMeds: Price and delivery differences compared
Embody vs BreezeMeds answers the key choice for telehealth GLP-1 access: Embody emphasizes a very low entry price for compounded semaglutide and fast free shipping, while BreezeMeds shows higher listed starts and a wider set of injectable and oral options. Early verdict: choose Embody for the lowest advertised compounded semaglutide price and fastest stated shipping; choose BreezeMeds if you need injectable plus oral product types and prefer to confirm product-level pricing and eligibility before enrolling.
See Embody $69/month semaglutide
Top differences: price, formulation options, shipping speed
Comparing Embody vs BreezeMeds across available evidence shows three distinctive differences: starting price, product format variety, and delivery and pricing transparency. Each is documented on the providers’ landing-page evidence and in captured summaries.
1. Starting price and entry cost
Embody lists compounded semaglutide at $69/month, cut from $299, and compounded tirzepatide at $119/month. BreezeMeds lists semaglutide injection starting at $199/month, tirzepatide injection starting at $299, and oral semaglutide and oral tirzepatide displayed from $399; a separate $169 figure appears without clear product association. Final pricing and billing commitments for BreezeMeds were not fully visible in the captured evidence.
Compare Embody pricing and details
2. Formulation and product types offered
Embody’s evidence emphasizes compounded semaglutide and compounded tirzepatide injections only. BreezeMeds shows both injectable and oral GLP-1 options: semaglutide injection, tirzepatide injection, oral semaglutide, and oral tirzepatide. BreezeMeds’ captured content notes that medication-specific approval status must be confirmed.
3. Shipping speed and delivery promises
Embody advertises free shipping with delivery in 1–2 days after clinician approval. BreezeMeds advertises discreet home delivery but does not provide a comparable fast delivery time in the captured evidence. Both platforms require a licensed clinician review; BreezeMeds specifically states treatment is available only when a licensed clinician determines it is medically appropriate.
Check BreezeMeds options and eligibility
Side-by-side snapshot
| Criteria | Embody | BreezeMeds |
|---|---|---|
| Semaglutide starting price | $69/month compounded semaglutide (was $299) | Semaglutide injection starting at $199/month; separate $169 figure not clearly tied to a product |
| Tirzepatide starting price | $119/month compounded tirzepatide | Tirzepatide injection starting at $299; oral tirzepatide displayed from $399 |
| Oral options | Not listed in captured evidence | Oral semaglutide and oral tirzepatide displayed from $399 |
| Shipping promise | Free shipping; arrives in 1–2 days after approval | Discreet home delivery; timing not specified in captured evidence |
| Compounded status and regulatory note | Compounded medications are not FDA approved and not reviewed by FDA for safety, effectiveness or quality | Compounded products, when offered, are not FDA-approved and must be confirmed; medication-specific approval status must be confirmed |
| Enrollment and clinician review | Prescription and telemed visits included; licensed provider review online | Online intake with clinician review; treatment only when clinically appropriate |
What the differences mean for you
If your primary concern is the lowest advertised monthly cost for compounded semaglutide and fast delivery after approval, the captured evidence supports that Embody positions itself for cost-driven patients with a simple telehealth workflow and no long-term membership. If you need multiple formulation types including oral GLP-1 options or want to confirm exact product-level pricing and state availability up front, BreezeMeds displays a wider set of injectable and oral options but captured pricing is higher and in some cases not fully tied to a product in the captured evidence.
Start Embody telehealth intake
Safety and regulatory notes
Both providers’ captured evidence includes regulatory cautions. Embody’s materials explicitly state that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. BreezeMeds’ captured evidence says medication-specific approval status must be confirmed and that branded and compounded products are not interchangeable. Both require clinician review before treatment.
Conclusion: choosing between Embody vs BreezeMeds
Embody vs BreezeMeds comes down to trade-offs documented in the captured evidence: Embody offers a notably lower advertised entry price for compounded semaglutide and a stated 1–2 day free shipping promise after approval. BreezeMeds displays a broader set of product formats including oral options and lists higher starting prices with some pricing items not clearly tied to specific products in the captured evidence.
Choose Embody if you want the lowest advertised compounded semaglutide entry price and fast free shipping and are comfortable with compounded medication options and fewer premium features. Choose BreezeMeds if you need injectable plus oral GLP-1 options and prefer to confirm product-level pricing, eligibility, and state availability before enrolling.